胸腺肽輔助治療對糖尿病合并肺結核患者治療效果及血清中免疫細胞水平的影響

以下是大綱或介紹,如需要完整的資料請購買下載. 本資料已審核過,內容保密,格式標準,質量保證.  
1.無需注冊登錄,購買下載后即可獲取該完整的資料.
2.購買后本站提供下載鏈接或聯系客服發送資料.
資料介紹

胸腺肽輔助治療對糖尿病合并肺結核患者治療效果及血清中免疫細胞水平的影響(論文4700字)
【摘要】 目的 探討胸腺肽注射液輔助治療糖尿病合并肺結核患者的臨床效果及患者血清中免疫細胞水平的影響。 方法 選取本院2014年6月至2016年6月在院治療,經T-spot.TB診斷為結核潛在感染的糖尿病患者98例,根據患者自愿原則分為采用常規治療的對照組和聯合胸腺肽輔助治療的對照組,對比兩組患者結核治療效果、血清中免疫細胞水平。結果: 觀察組患者強化期結束、療程結束涂陽轉陰分別為37、42例,培養轉陰分別為36例、41例,與對照組患者數據比較無差異,P>0.05;對比不同類型患者血清中免疫細胞水平,結果發現正常人群血清中Treg細胞水平為1.3±0.6,明顯低于糖尿病和糖尿病合并肺結核患者,而Th17細胞水平為3.5±1.2,明顯高于糖尿病患者和糖尿病合并肺結核患者,差異顯著,具有統計學意義;兩組患者治療前Treg細胞核Th17細胞水平對比無差異,具有可比性,隨著治療的進展Treg細胞含量依次下降,但觀察組患者強化期結束和療程結束Treg含量分別為2.2±0.8、1.7±0.5,相比含量低于對照組,Th17細胞含量逐漸上升,但是觀察組患者強化期結束和療程結束Th17細胞含量分別為2.5±0.6,3.1±0.7,明顯高于對照組患者,差異顯著,具有統計學意義;兩組患者治療后癥狀發生情況對比無差異,治療后觀察組患者乏力、盜汗、食欲下降、咳嗽、咳痰消失率分別為88.89%、87.10%、86.36%、75.0%、88.89%,明顯高于對照組,差異顯著,具有統計學意義。結論:在強化抗癆治療的同時采用胸腺肽注射輔助提高患者免疫功能,有助于改善患者T細胞亞群,促進患者臨床癥狀的緩解,值得臨床推廣運用。
【關鍵詞】 胸腺肽;糖尿病合并肺結核;效果;免疫
Effect of immune cells and serum level of clinical effect in patients with Thymopeptide Enteric Injection adjuvant treatment of diabetes complicated with pulmonary tuberculosis
[Abstract] Objective  To investigate the effect of immune cells and serum level of clinical effect in patients with Thymopeptide Enteric Injection adjuvant treatment of diabetes complicated with pulmonary tuberculosis..Methods 98 cases of diabetic patients with tuberculosis infection in our hospital from June 2014 to June 2016 , diagnosed by T-spot.TB in , according to the principle of voluntary patients were divided into the control group and the control group with conventional therapy combined with thymosin adjuvant therapy, immune cell level contrast effect, the treatment group of two patients with tuberculosis in serum.Result:Patients in the observation group at the end of the end of the treatment, strengthening the smear negative were 37, 42 cases were culture negative were 36 cases, 41 cases had no difference compared with the control group, the patient data P>0.05; serum levels of immune cells in patients with different types of contrast, found that the normal serum level of Treg cells was 1.3±.6. Was significantly lower than that in patients with diabetes and diabetes combined with pulmonary tuberculosis, and the level of Th17 cells was 3.5± 1.2, significantly higher than in patients with diabetes and diabetes combined with pulmonary tuberculosis was significantly different, with statistical significance; the two groups were compared before Treg cell nuclear Th17 cells had no significant difference, comparable with the progress in the treatment of Treg cells in order to decrease, but the patients in the observation group enhanced Treg content and the end of treatment were 2.2± 0.8, 1.7± 0.5, compared were lower than control group, Th17 cell content Increased gradually, but the patients in the observation group were enhanced Th17 cells content end and course of treatment were 2.5±0.6, 3.1± 0.7, significantly higher than in the control group, the difference was statistically significant; two groups of patients after treatment of symptoms compared to no difference, the observation group after treatment in patients with fatigue, sweating, loss of appetite, cough and sputum disappear rate were 88.89%, 87.10%, 86.36%, 75%, 88.89%, significantly higher than the control group, the difference was statistically significant.Conclusion:At the same time: strengthening anti tuberculosis treatment with thymosin injection auxiliary enhancing immune function, help to improve the T cell subsets of patients, promote the clinical symptom remission, is worthy of clinical application
[Key words]Thymosin; diabetes mellitus complicated with pulmonary tuberculosis; immune effect

无错六肖王财神